Taysha Gene Therapies Inc (TSHA) Stock Price, Quote & News

Company Profile

Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency; TSHA-113 for t...

Industry: Biotechnology

Sector: Healthcare

Phone: 214 612 0000

Website: www.tayshagtx.com

Address:

3000 Pegasus Park Drive, Suite 1430, Dallas, United States

prismmarketview Dec. 6 at 4:25 PM

Taysha Gene Therapies (Nasdaq: $TSHA) grants stock options for 212,000 shares to two new employees under its 2023 Inducement Plan, with a $4.49 exercise price and a four-year vesting schedule, in line with Nasdaq Listing Rule 5635(c)(4). https://prismmarketview.com/press-release/?qmodStoryID=4888670633811428

0 · Reply

jojo1408 Dec. 4 at 3:45 PM

$TSHA

0 · Reply

Oncourtking127 Dec. 4 at 2:57 PM

$TSHA 👀

0 · Reply

DaBullRunner Dec. 4 at 1:42 PM

$TSHA there it goes 🚨EPOW🚨 just received a $30M contract That is HUGE for a tiny company This should be at least $2 🎯✅ I’m even willing to put some of my TSLA COIN profits into EPOW👇💰💰💰

0 · Reply

Quantumup Dec. 4 at 12:33 PM

Goldman Sachs⬆️ $TSHA to a Buy-$11 from an Early-Stage Biotech Designation $NGNE $NVS ACAD AVXL ALPMY Here's what Goldman Sachs had to say: https://x.com/Quantumup1/status/1996556492133032307?s=20

0 · Reply

quickaspeter Dec. 4 at 12:01 PM

$TSHA Let’s go! 💥🚀💰

0 · Reply

notreload_ai Dec. 4 at 11:29 AM

Goldman Sachs upgrades $TSHA to Buy with an $11 target, citing strong confidence in the company’s Rett syndrome program and REVEAL study (TSHA-102) expectations. https://notreload.xyz/goldman-sachs-upgrades-taysha-on-rett-study-outlook/

0 · Reply

quickaspeter Nov. 26 at 9:54 PM

$TSHA - Jefferies Financial Group boosted its Taysha stake by 4,105.3% in Q2, acquiring 10,068,479 shares to hold 10,313,733 shares — about a 4.80% ownership. - TSHA trades near $4.19 with a market cap of $1.15 billion, a 12‑month range of $1.05–$5.51, and reported a quarterly EPS of ($0.09) with analysts forecasting roughly -0.35 EPS for the year. - Institutional investors own roughly 77.7% of the stock, and analysts maintain a consensus "Moderate Buy" with a $10.30 average target after several price‑target upgrades. https://www.marketbeat.com/instant-alerts/filing-jefferies-financial-group-inc-acquires-10068479-shares-of-taysha-gene-therapies-inc-tsha-2025-11-24/

0 · Reply

quickaspeter Nov. 26 at 4:35 PM

$RNA $SRPT $TSHA Amazing…❤️💥🚀💰

0 · Reply

jojo1408 Nov. 26 at 12:10 PM

$TSHA

0 · Reply

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Nov 4, 2025, 2:36 PM EST - 4 weeks ago

Taysha Gene Therapies, Inc. (TSHA) Q3 2025 Earnings Call Transcript

Nov 4, 2025, 7:00 AM EST - 4 weeks ago

Taysha Gene Therapies Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Oct 28, 2025, 8:00 AM EDT - 5 weeks ago

Taysha Gene Therapies to Release Third Quarter 2025 Financial Results and Host Conference Call and Webcast on November 4

Oct 16, 2025, 4:01 PM EDT - 7 weeks ago

Taysha Gene Therapies Regains Full Rights to Lead TSHA-102 Program in Clinical Evaluation for the Treatment of Rett Syndrome

Oct 9, 2025, 8:00 AM EDT - 2 months ago

Taysha Gene Therapies Presents New Supplemental Data Analysis from Part A of the REVEAL Phase 1/2 Trials for TSHA-102 in Rett Syndrome at the 54th CNS Annual Meeting

Oct 6, 2025, 10:07 AM EDT - 2 months ago

Taysha Gene Therapies: Breakthrough Rett Program With BLA Acceleration Potential

Oct 2, 2025, 8:00 AM EDT - 2 months ago

Taysha Gene Therapies Announces FDA Breakthrough Therapy Designation and Provides Positive Regulatory Update on TSHA-102 in Rett Syndrome

Aug 12, 2025, 1:38 PM EDT - 4 months ago

Taysha Gene Therapies, Inc. (TSHA) Q2 2025 Earnings Call Transcript

Aug 12, 2025, 8:01 AM EDT - 4 months ago

Taysha Gene Therapies Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 5, 2025, 4:05 PM EDT - 4 months ago

Taysha Gene Therapies to Release Second Quarter 2025 Financial Results and Host Conference Call and Webcast on August 12

Jun 3, 2025, 5:17 PM EDT - 6 months ago

Taysha Gene Therapies Announces Details for Oral Presentations at the 2025 IRSF Rett Syndrome Scientific Meeting Reviewing Recent Updates from the TSHA-102 Clinical Program

May 29, 2025, 1:06 PM EDT - 6 months ago

Why Is Taysha Gene Therapies Stock Trading Higher On Thursday?

May 28, 2025, 10:40 PM EDT - 6 months ago

Taysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

May 28, 2025, 4:02 PM EDT - 6 months ago

Taysha Gene Therapies Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

May 28, 2025, 4:01 PM EDT - 6 months ago

Taysha Gene Therapies Announces Pivotal Part B Trial Design Details for TSHA-102 in Rett Syndrome Enabled by IRSF Natural History Data and Positive Clinical Data from Part A of the REVEAL Adult/Adolescent and Pediatric Trials Evaluating TSHA-102

May 15, 2025, 2:07 PM EDT - 7 months ago

Taysha Gene Therapies, Inc. (TSHA) Q1 2025 Earnings Call Transcript

May 15, 2025, 8:00 AM EDT - 7 months ago

Taysha Gene Therapies Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 8, 2025, 4:05 PM EDT - 7 months ago

Taysha Gene Therapies to Release First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 15

Mar 31, 2025, 2:25 PM EDT - 8 months ago

Drug stocks sink as FDA's top vaccine official is ousted in Trump overhaul

BNTX NVAX SLDB SRPT XBI

Feb 26, 2025, 2:54 PM EST - 10 months ago

Taysha Gene Therapies, Inc. (TSHA) Q4 2024 Earnings Call Transcript

Feb 26, 2025, 8:00 AM EST - 10 months ago

Taysha Gene Therapies Reports Full-Year 2024 Financial Results and Provides Corporate Update

Feb 19, 2025, 8:00 AM EST - 10 months ago

Taysha Gene Therapies to Release Full-Year 2024 Financial Results and Host Conference Call and Webcast on February 26

Jan 27, 2025, 7:53 PM EST - 11 months ago

Taysha Gene Therapies Is Showing Promise For Rett Syndrome

Nov 14, 2024, 8:25 AM EST - 1 year ago

Advance Auto Parts Posts Weak Results, Joins Harrow, Taysha Gene Therapies And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

AAP

Nov 13, 2024, 10:48 PM EST - 1 year ago

Taysha Gene Therapies, Inc. (TSHA) Q3 2024 Earnings Call Transcript

Nov 13, 2024, 4:01 PM EST - 1 year ago

Taysha Gene Therapies Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Oct 22, 2024, 8:00 AM EDT - 1 year ago

Taysha Gene Therapies to Present Biodistribution Data from an Analysis Evaluating AAV9 Gene Therapy Delivery at the Upcoming 31st Annual ESGCT Congress

Oct 14, 2024, 12:55 AM EDT - 1 year ago

Taysha Gene Therapies: Unjustified Sell-Off - Enough Cash Runway And Promising Rett Syndrome Data

Aug 12, 2024, 12:08 PM EDT - 1 year ago

Taysha Gene Therapies, Inc. (TSHA) Q2 2024 Earnings Call Transcript

Aug 12, 2024, 8:01 AM EDT - 1 year ago

Taysha Gene Therapies Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Jun 26, 2024, 7:36 AM EDT - 1 year ago

Worthington Enterprises Posts Downbeat Results, Joins Taysha Gene Therapies, General Mills And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

GIS

Jun 18, 2024, 11:42 AM EDT - 1 year ago

What's Going On With Taysha Gene Therapies Stock Tuesday?

Jun 18, 2024, 7:30 AM EDT - 1 year ago

Taysha Gene Therapies Announces Positive Clinical Data Across Adult and Pediatric Patients from Low Dose Cohort in Ongoing REVEAL Phase 1/2 Trials Evaluating TSHA-102 in Rett Syndrome

Jun 12, 2024, 7:00 AM EDT - 1 year ago

Taysha Gene Therapies to Present Clinical Data from Both REVEAL Phase 1/2 Trials During Company-Hosted Webcast and at 2024 IRSF Rett Syndrome Scientific Meeting

May 15, 2024, 4:55 AM EDT - 1 year ago

Taysha Gene Therapies, Inc. (TSHA) Q1 2024 Earnings Call Transcript

May 14, 2024, 4:01 PM EDT - 1 year ago

Taysha Gene Therapies Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 7, 2024, 4:05 PM EDT - 1 year ago

Taysha Gene Therapies to Release First Quarter 2024 Financial Results and Host Conference Call and Webcast on May 14

May 2, 2024, 8:00 AM EDT - 1 year ago

Taysha Gene Therapies Announces Regenerative Medicine Advanced Therapy (RMAT) Designation Granted by U.S. FDA for TSHA-102 in Rett Syndrome

Mar 20, 2024, 12:30 PM EDT - 1 year ago

Taysha: Initial Rett Syndrome Data Leads To Other 2024 Catalysts

Mar 19, 2024, 9:04 PM EDT - 1 year ago

Taysha Gene Therapies, Inc. (TSHA) Q4 2023 Earnings Call Transcript

Mar 19, 2024, 4:01 PM EDT - 1 year ago

Taysha Gene Therapies Reports Full Year 2023 Financial Results and Provides Corporate and Clinical Updates

Mar 14, 2024, 4:26 PM EDT - 1 year ago

Taysha Gene Therapies to Release Full-Year 2023 Financial Results, Provide Corporate and Clinical Updates and Host Conference Call on March 19

Feb 29, 2024, 8:00 AM EST - 1 year ago

Taysha Gene Therapies Announces Updates to TSHA-102 Clinical Program in Rett Syndrome

Feb 15, 2024, 4:01 PM EST - 1 year ago

Taysha Gene Therapies Provides Update on Deprioritized Pipeline Programs

Jan 22, 2024, 8:00 AM EST - 2 years ago

Taysha Gene Therapies Announces Poster Presentation on TSHA-102 in Rett Syndrome at Upcoming British Paediatric Neurology Association 2024 Annual Conference

Jan 15, 2024, 9:30 AM EST - 2 years ago

3 Growth Stocks That Could Go Parabolic in 2024

ABCL CERS

Jan 10, 2024, 8:00 AM EST - 2 years ago

Taysha Gene Therapies Announces First Pediatric Patient Dosed with TSHA-102 in REVEAL Phase 1/2 Pediatric Trial in Rett Syndrome

Dec 19, 2023, 7:30 AM EST - 2 years ago

Trinity Capital Inc. Provides $40 Million Term Loan to Taysha Gene Therapies

TRIN

Nov 29, 2023, 8:00 AM EST - 2 years ago

Taysha Gene Therapies Announces Expanded Eligibility in REVEAL Phase 1/2 Adult Trial to Include Adolescent Rett Syndrome Patients

prismmarketview Dec. 6 at 4:25 PM

0 · Reply

jojo1408 Dec. 4 at 3:45 PM

$TSHA

0 · Reply

Oncourtking127 Dec. 4 at 2:57 PM

$TSHA 👀

0 · Reply

DaBullRunner Dec. 4 at 1:42 PM

0 · Reply

Quantumup Dec. 4 at 12:33 PM

0 · Reply

quickaspeter Dec. 4 at 12:01 PM

$TSHA Let’s go! 💥🚀💰

0 · Reply

notreload_ai Dec. 4 at 11:29 AM

0 · Reply

quickaspeter Nov. 26 at 9:54 PM

0 · Reply

quickaspeter Nov. 26 at 4:35 PM

$RNA $SRPT $TSHA Amazing…❤️💥🚀💰

0 · Reply

jojo1408 Nov. 26 at 12:10 PM

$TSHA

0 · Reply

stockmoe12 Nov. 25 at 10:42 PM

$TSHA 15+ buyout anytime now

0 · Reply

jmang21 Nov. 25 at 3:39 PM

$TSHA what is next catalyst?? Long since $.77

1 · Reply

wwmeinc Nov. 24 at 5:29 PM

$RNA $TSHA $SRPT This gene news today out of the UK has given the space/sector some good coverage...not company specific per se...charity funding kept the science going in the end...just good/great to see science coming through....glta "In 2020 the university announced a partnership with a small US biotech company Avrobio, to conduct a clinical trial. But three years later the company handed back the licence to the university, following poor results from another gene therapy study and a lack of funds. The first-in-human trial, which would soon help Oliver, was in jeopardy before it had even begun. Prof Jones: "We had to move very quickly to try to save the whole idea and find another sponsor and another source of funding." It was then that British medical research charity, LifeArc, stepped in, providing £2.5m of funding." https://www.bbc.com/news/articles/c5y0y56x6veo

0 · Reply

warren5677 Nov. 21 at 6:47 PM

$TSHA Cantor Fitzgerald increases PT for TSHA to $19 from $13 keeps overweight rating 11/21/25.

0 · Reply

quickaspeter Nov. 19 at 1:36 PM

$TSHA Diamond-in-the-Rough…thanks for sharing 💥🚀💰

0 · Reply

Jestofunk Nov. 18 at 10:42 PM

$TSHA just keep holding and I hope you bought the dip

0 · Reply

NVDAMillionaire Nov. 18 at 10:43 AM

$TSHA Really good write-up that perfectly summarizes TSHA's present situation. So if you want to bring your TSHA knowledge up to date or just discover TSHA, this is required reading. https://beyondspx.com/quote/TSHA/analysis/taysha-gene-therapies-unlocking-rett-syndrome-s-potential-with-breakthrough-gene-therapy-nasdaq-tsha

0 · Reply

biotech Nov. 14 at 1:40 PM

$SGMO buyout by Astellas expected ? Q: #Astellas thoughts on gene therapy development + commerc.? why end $TSHA? STRATEGIC A: "Astellas is still committed to developing gene therapy." #Astellas says "We see more platform development together with $SGMO to actually create next generation of gene therapy.” "

2 · Reply

Quantumup Nov. 14 at 12:45 PM

Cantor reit $TSHA OW13 $NGNE $ACAD Neurogene (NGNE, NC) reported updated Phase 1/2 data for its ICV-administered gene therapy NGN-401 in Rett syndrome (rare neurodevelopmental disorder). From our conversations, we believe investors have spent more time focusing on key differences between the approaches, although there have also been questions about how to interpret cross-data comparisons with Taysha's TSHA-102 (intrathecally administered AAV9-based gene therapy). NGNE shares closed -15% today (vs. -8% for TSHA), which we believe could be in part related to some of the treatment-related AEs that were disclosed in NGNE's release. While we believe both companies are assessing natural history datasets to understand what is deemed a milestone, skill, etc., we don't fully appreciate or understand what analysis NGNE evaluated their data against. Nor do we fully understand the statistical analysis plan NGNE has put into place to fully appreciate what is deemed a "responder" in their pivotal trial.

0 · Reply

Houseofsweeps Nov. 13 at 3:03 PM

$NGNE $TSHA jumped 70% from good results. Ngne had less patients achieve more milestones and it’s down 8% today 🤣😅

0 · Reply

IN0V8 Nov. 6 at 5:56 AM

$TSHA Buy Jefferies raises target price to $11 from $9

0 · Reply

warren5677 Nov. 5 at 9:56 PM

$TSHA Looks like someone wanted in.

0 · Reply

Market Cap	1.38B
Revenue (ttm)	8.33M
Net Income (ttm)	-89.30M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-1,072.03%
Debt to Equity Ratio	0.17

Volume	3,004,000
Avg Vol	6,841,668
Day's Range	N/A - N/A
Shares Out	273.92M
Stochastic %K	84%
Beta	1.06
Analysts	Strong Sell
Price Target	$10.57